Pediatric Trial Evaluating COVID-19 Oral Antiviral Paxlovid Begins
The EPIC-PEDS study will include approximately 140 patients less than 18 years of age with a confirmed diagnosis of COVID-19 who are at risk of progression to severe disease.
Infectious Diseases
MPR Weekly Dose Podcast Episode 104
This week, two new approvals for atopic dermatitis; Warnings around counterfeit HIV treatments; Some US indications for Zydelig are withdrawn; CDC pediatric flu vaccine study results; And an FDA warning against certain COVID-19 antibody tests.
PreHevbrio, a 3-Antigen Hepatitis B Vaccine, Gets FDA Approval
PreHevbrio contains the small (S), middle (pre-S2) and large (pre-S1) hepatitis B surface antigens.
COVID-19 Vaccine-Induced Immunity More Protective Than Infection
Odds of laboratory-confirmed COVID-19 more than fivefold higher for unvaccinated patients with previous infection versus vaccinated persons
